glp-1 differences Comparing Ozempic, Wegovy and Other Drugs image1.png
Description
Cardiovascular outcomes trials of Incretin-Based therapies
[DOI] [PubMed] [Google Scholar] 17.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al
6 Months $2200
Asnicar F, Leeming ER, Dimidi E, et al
The key differentiator mechanistically is GCGR activation: tirzepatide has no glucagon component
Based on existing registry data (e.g., FDA and EMA data), the patient should be informed that while there is no clear evidence of teratogenicity, intensified prenatal monitoring is required
